OncoMatch/Clinical Trials/NCT07193550
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Is NCT07193550 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Zanzalintinib for bone sarcomas.
Treatment: Zanzalintinib — To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — advanced/metastatic
Patients must have relapsed or become refractory to conventional therapy, receiving at least 1 prior line of systemic therapy unless no standard of care exists.
Cannot have received: zanzalintinib (zanzalintinib)
Prior treatment with zanzalintinib.
Cannot have received: VEGF-targeted TKI (cabozantinib, regorafenib, pazopanib)
Patients previously treated with other VEGF-targeted TKIs (including but not limited to cabozantinib, regorafenib, pazopanib, or similar).
Cannot have received: small molecule kinase inhibitor
Receipt of any small molecule kinase inhibitor (including investigational) within 2 weeks before first dose of study treatment.
Cannot have received: investigational study drug and/or procedure
Prior receipt of an investigational study drug and/or procedure within 21 days of study day 1.
Cannot have received: anti-tumor therapy
Anti-tumor therapy within 21 days of study day 1 including chemotherapy, antibody therapy, or other investigational agent.
Cannot have received: radiation therapy for bone metastasis
Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks, or systemic treatment with radionuclides within 6 weeks before first dose of study treatment
Lab requirements
Blood counts
ANC ≥ 1500/mm3 (growth factor/G-CSF permitted); Platelet count ≥ 100,000/mm3; Hemoglobin > 9 g/dL
Kidney function
calculated creatinine clearance ≥ 40 mL/min (≥ 0.67 mL/sec) using the Cockcroft Gault equation
Liver function
AST and ALT < 3 x ULN and total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN), serum albumin ≥ 2
Cardiac function
NYHA class 2B or better; QTcF ≤ 470 ms within 14 days per ECG before first dose of study treatment
Hematological function, as follows: Absolute neutrophil count (ANC) ≥ 1500/mm3 (growth factor/G-CSF permitted); Platelet count ≥ 100,000/mm3; Hemoglobin > 9 g/dL. INR ≤ 1.5 and activated partial thromboplastin time (aPTT) < 1.2 x upper limit of normal (ULN), except subjects on anticoagulation. Renal function as follows: calculated creatinine clearance ≥ 40 mL/min (≥ 0.67 mL/sec) using the Cockcroft Gault equation. Hepatic function as follows: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN and total bilirubin ≤ 1.5 x ULN (for subjects with Gilberts's disease ≤ 3 x ULN), serum albumin ≥ 2. Cardiac: NYHA class 2B or better; QTcF ≤ 470 ms within 14 days per ECG before first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07193550 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior zanzalintinib, VEGF-targeted TKI, small molecule kinase inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify